Business
Soleno Therapeutics Announces Presentations at the 2022 European Congress of Endocrinology
REDWOOD CITY, Calif., May 19, 2022 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company
About this update from Soleno Therapeutics, Inc.
[{"type":"text","content":"REDWOOD CITY, Calif., May 19, 2022 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced presentations at the upcoming 2022 European Congress of Endocrinology (ECE), which is being held May 21-24, 2022, in Milan, Italy. Details of the presentations are as follows: 2022 European Congress of Endocrinology (ECE) Title:DCCR UpdateFormat:Presentation at the International Prader-Willi syndrome Meeting 2022 organized by INfoRMEd – PWS (the International Netwrok for Research, Managament and Education on adults with PWS) and the European Society of EndocrinologyPresenter:Dr. Evelien Gevers on behalf of the DESTINY PWS InvestigatorsDateSaturday, May 21, 2022Time:12:10 – 12:30 PM CET Title:Long-Term Safety of Diazoxide Choline Extended-Release (DCCR) Tablets in Patients with Prader-Willi SyndromeFormat:E-Poster -- Programme Code: EP360 / Submission Number 2044Presenter:Dr. Evelien Gevers on behalf of the DESTINY PWS Investigators Title:Comparison of hyperphagia and problem behaviors in participants with Prader-Willi syndrome (PWS) receiving Diazoxide Choline Extended-Release (DCCR) with matched participants in PATH for PWS (PfPWS)Format:Poster -- Programme Code: P77 / Submission Number 789Presenter:Dr. Evelien Gevers on behalf of the DESTINY PWS Investigators and the PATH for PWS InvestigatorsDate:Sunday, May 22, 2022 The copy of the posters will be available in the Investors section on the Company’s website at www.soleno.life after presentation at the meeting. About Soleno Therapeutics, Inc.Soleno is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. The company’s lead candidate, DCCR, a once-daily oral tablet for the treatment of Prader-Willi syndrome (PWS), is currently being evaluated in an ongoing Phase 3 clinical development program. For more information, please visit www.soleno.life. Corporate Contact:Brian RitchieLifeSci Advisors, LLC212-915-2578 \nSource: Soleno Therapeutics","length":5410,"tagName":"div"}]